+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain Publishes NGS-Based RNA Sequencing Market Report 2021-2031

11 May 2021

Visiongain has published a new report on NGS-Based RNA Sequencing Market Report 2021-2031: Forecasts by Component (Sequencing Platforms, Sequencing Products, Kits and Reagents, Services), by Technology (Ion Semiconductor Sequencing, Pyrosequencing, Synthesis Sequencing (SBS), Real Time Sequencing (SMRT), Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing), by End-user (Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories) AND Regional and Leading National Market Analysis PLUS Analysis of Leading RNA Sequencing Companies AND COVID-19 Recovery Scenarios.

Global NGS Based RNA Sequencing market was valued at US$ xx million in 2020 and is projected to reach at a market value of US$ xx million by 2031. NGS based RNA Sequencing is a technique used to analyse the presence and sequences of RNA in a biological sample using next generation sequencing (NGS). The technology is a sensitive and accurate tool for measuring expressions across the transcriptome and provides researchers with visibility into previously unrevealed variations taking place in disease states, against therapeutics, under varying environmental settings, and across wide ranging study designs. The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.

COVID-19 Impact on Global NGS Based RNA Sequencing Market
NGS based RNA Sequencing technology is playing a critical role in fighting COVID-19 by identifying the coronavirus causing COVID-19 (SARS-CoV-2) along with its mutations, transmission and research on genetics. COVID-19 has highlighted the need for genomic sequencing tools from initial detection of emerging virus to diagnostic. Major concern about novel SARS-CoV-2 coronavirus variants (B.1.1.7 strain and B1.351 strain) spreading rapidly across world underscores the need for further sequencing technologies to identify mutations and control the spread of strain variants. These factors are promoting the development and investments in the NGS based RNA Sequencing industry by big pharma and technology players to support new diagnostic test methods.

Market Drivers

Rising prevalence of cancer to boost the market
The increasing research in the healthcare space through next generation sequencing, which has been used to create biomarkers and therapies in cancer disease, will drive the NGS dependent RNA Sequencing Market. The global cancer incidence is projected to increase to 27.5 million new cases and 16.3 million deaths by 2040. Therefore, the rising occurrence of cancer diseases will facilitate the adoption of genomic tools.

Increasing funding support from government
Growing government funding support for the advancement of life-science projects would drive the NGS-based RNA Sequencing market in the future. Several programmes including National Cancer Institute (NCI) funding programme support the academic researchers, organizations and physicians in the study and analysis of genomic sequencing. These funding aims to advance scientific research by bridging data gaps in vast amounts of data generated by comprehensive molecular descriptions and investigations into the underlying aetiology of cancer growth.

Market Opportunities

Immense opportunities to flourish in developing nations
COVID-19 has provided opportunities for emerging countries to conduct genomic research to benefit the global population through early detection. These economies plan to invest in genomic research to combat infectious diseases and non-communicable diseases that affect large populations in order to improve public health.

Advancements in the genomic sequencing field
Advanced technologies, such as advances in RNA structural techniques, large-scale sequencing, and modern computer simulations to analyse RNA structure with remarkable performance, are attempting to reveal a large number of RNA structures at new genomic scales. NGS-based RNA Sequencing has largely replaced the microarray technique because it tends to be more detailed and effective for low-level transcripts.

Competitive Landscape
Some of the top companies in the NGS Based RNA Sequencing Market profiled in the report include Illumina, Thermo Fisher Scientific, Takara Bio, Zymo Research, F. Hoffmann-La Roche, QIAGEN, PerkinElmer, Pacific Biosciences of California, Oxford Nanopore Technologies, Macrogen, Hamilton, Genewiz, BGI, Agilent Technologies, Gatc Biotech. The report highlights various key data points such as company's overview, financial status, company positioning analysis, recent developments in the area of next generation sequencing and initiatives undertaken by the company to gain competitive edge in the market.

Recent Developments
In April 2021, Illumina, the global genomics leader in providing next-generation sequencing (NGS) solutions has announced partnership with a private clinical-stage biopharmaceutical company, Kartos Therapeutic to create an NGS based TP53 companion diagnostic for For TP53-Haboring cancer indications. The TSO 500 from Illumina is primarily used for study, but it can detect 523 established and potential cancer biomarkers. TSO 500 will be used as a sample with peripheral whole blood in the latest diagnostic. Additionally, Illumina has signed agreements with other gene-based companies including Kura Oncology, Qiagen and Merck.

In Feb 2021, QIAGEN, the global leader in precision medicine has extended their partnership with a biotechnology firm, INOVIO pharmaceuticals through a master collaboration agreement to advance liquid biopsy-based diagnostic products based on next-generation sequencing technology. The collaboration aims to complement INOVIO's therapies in advanced cervical dysplasia.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Press Release: Peripheral Vascular Device Market Report 2024-2034

The global Peripheral Vascular Devices market is estimated at US$12.49 billion in 2024 and is projected to grow at a CAGR of 8.5% during the forecast period 2024-2034.

30 April 2024


Press Release: Drug Delivery Technologies Market Report 2024-2034

The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

23 April 2024


Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024


Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024